NASDAQ OMX

CloudCraze and Deloitte Digital Formalize Alliance to Provide Leading B2B Commerce in the Cloud

Dela

Deloitte Digital's experience in digital transformation and CloudCraze's native Salesforce commerce platform will empower B2B customers to transform their business through SaaS

CHICAGO, May 04, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has collaborated with Deloitte Digital and awarded the leading creative digital consultancy Platinum Partner status, the highest level in the CloudCraze partner program. Together, they deliver full-service cloud-based B2B commerce solutions for enterprises in the manufacturing and consumer goods industry that are quick to implement, Salesforce-integrated and more profitable long term.

The alliance enhances the value that both companies bring to B2B commerce customers through the combination of Deloitte Digital's deep technological experience, industry insight and full suite of implementation services and CloudCraze's cloud-based B2B platform delivering speed to revenue, flexibility and customer focus. Deloitte Digital's vast industry experience and robust offerings have already made them instrumental for implementations with several of CloudCraze's high profile customers, including a large multi-national beverage and brewing company and one of the largest member-owned agricultural cooperatives.

"Deloitte Digital's creative, cloud-based approach to digital transformation has been a major asset for our customers over the years and our combined solutions provide unmatched value," said Ray Grady, president and chief customer officer at CloudCraze. "We look forward to leveraging Deloitte Digital's vast industry experience and are excited to have them on board as an integral CloudCraze Platinum Partner."

CloudCraze has worked closely with Deloitte Digital to build accelerated solutions. They combine a unique set of solutions and platforms, including Salesforce and CloudCraze commerce on Salesforce, to offer Deloitte customers a unified customer experience across the digital enterprise. The interactive platform was developed in response to customer need for a more robust integration of digital cloud platforms across CRM, commerce, digital marketing, and other customer engagement channels.

"Working with CloudCraze has allowed us to create even more engaging, strategic and flexible B2B commerce solutions with CloudCraze's unique speed-to-market and cloud-first, SaaS-based approach to customer engagement," said Paul do Forno, managing director, Deloitte Consulting LLP, and commerce and content practice lead at Deloitte Digital. "CloudCraze's unique offerings strengthen the digital ecosystem platform we have built and we're excited about the value the strategic alliance will bring our combined customer base."

This alliance comes at a time of growing importance for robust digital offerings in B2B. Estimates from Gartner show the digital commerce platform market will have grown at a compound annual growth rate of over 15 percent from 2015 through 2020. With a cloud-first, customer-centric approach to commerce, the CloudCraze and Digital Deloitte's joint services will enable B2B companies to stay ahead of the SaaS adoption curve, offering them a more efficient and engaging approach to commerce.

About CloudCraze
CloudCraze delivers robust B2B commerce native on Salesforce. It allows businesses to generate online revenue fast and easily scale for growth. Its Customer-First Commerce model puts the customer at the core, informing every interaction with data across commerce, sales, marketing, service and more. With the Salesforce's trusted infrastructure and core capabilities, CloudCraze provides infinite flexibility to extend functionality, add products and channels, and conduct billions of dollars in transactions anywhere. CloudCraze powers Customer-First Commerce for industry leaders such as AB InBev, Barry-Callebaut, Coca-Cola, Ecolab, GE, Kellogg's, L'Oreal, Symantec, and WABCO.

CloudCraze is funded by Insight Venture Partners and Salesforce Ventures.  

CloudCraze is recognized in The Forrester Wave(TM): B2B Commerce Suites, Q1 2017 and as a Visionary in the Gartner Magic Quadrant for Digital Commerce 2017.

About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including 80 percent of the Fortune 500 and more than 6,000 private and middle market companies. Our people work across more than 20 industry sectors to deliver measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Media contacts
Rachel Gulden
Senior Account Executive
rachel.gulden@walkersands.com
312.267.0530




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CloudCraze via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept.  21, 2017  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech

At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58Pressmeddelande

LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service.  As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00Pressmeddelande

Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00Pressmeddelande

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea

Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00Pressmeddelande

Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23Pressmeddelande

DANVERS, Mass., Sept.  20, 2017  (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum